Mounjaro®
Starting from £179.99/mo
Start journey Learn moreKnowing when to increase your Wegovy dose comes down to three things: how long you've been on your current dose, how well you're tolerating it, and whether your weight loss has plateaued. Wegovy follows a stepwise titration schedule — 0.25mg, 0.5mg, 1.0mg, 1.7mg, then 2.4mg — with roughly four weeks at each level before moving up, as set out in the NHS patient guidance on semaglutide. That schedule exists for good reason, and your prescriber decides every step. These aren't decisions to make unilaterally, or to rush because a new pen is sitting in the fridge.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide is titrated gradually because the GI side effects) nausea, loose stools, reflux, are most pronounced when the dose first changes. The four-week window isn't a buffer built in for convenience; it gives your gut enough time to adjust before absorbing a bigger hit. Most people find that whatever discomfort shows up in week one or two of a new dose has eased considerably by week four.
So the first question to ask yourself is simple: have you been at your current dose for at least four weeks? If the answer is no, there's nothing further to assess, the time hasn't come yet. If you're unsure of your exact start date, your dispatch confirmation email or DPD tracking history usually tells you. (It's worth keeping a note of when each pen starts, especially around holidays or if a delivery falls near a bank holiday.)
One thing that catches people out: ordering late in a four-week cycle can compress that window. If you order by 12pm on a weekday, Wegovy through nume ships the same day and arrives the next working day, but building that rhythm into a reliable routine takes a little planning in the first month or two.
The titration schedule assumes the current dose is well tolerated before the next step begins. 'Well tolerated' doesn't mean you've felt nothing; it means any GI symptoms have settled to a level that isn't affecting your daily life. Mild nausea that comes and goes around injection day is common and expected. Persistent vomiting, significant abdominal pain, or symptoms that haven't eased four weeks in are different, those are signals to hold the dose where it is and talk to your prescriber rather than moving up.
There's also a rarer but serious side effect worth knowing: severe, persistent stomach pain that radiates to the back can be a sign of pancreatitis. The MHRA issued specific guidance on this risk for GLP-1 medicines in January 2026, and urgent medical assessment is the right response, not a dose adjustment. You can report suspected side effects via the MHRA Yellow Card scheme if you experience anything unexpected.
For most people, the question at week four is: 'Do I feel broadly okay on this dose?' If yes, the next step becomes possible. If not, the clinical conversation is about why, and whether extending the current dose for another four weeks, or longer, makes more sense than pushing forward.
Reaching a plateau on your current dose is the moment most people start wondering about going higher. A plateau can be real (the dose is no longer producing further loss) or it can be a temporary slowdown caused by the body adapting. Four to six weeks without movement on the scales, alongside good adherence to the dose and lifestyle changes, is generally when the question of increasing your Wegovy dose becomes worth raising with your prescriber.
But here's the nuance: a plateau alone doesn't automatically mean you should move up. The full picture matters, your current dose, how long you've been on Wegovy overall, your appetite suppression, your side effect history, and whether you're at or near the maintenance dose already. NICE's appraisal of semaglutide for weight management (TA875) notes that if less than 5% weight loss has occurred after six months on the maintenance dose, continuing should be reviewed. That's a clinical benchmark, not a self-assessment tool.
If you're weighing up costs alongside progress, the guide to Wegovy pricing in the UK covers what to expect at each stage. And if you want to understand how dose increases fit into the broader titration picture, the overview of Wegovy doses and strengths explains each step in context.
The short answer: raise it in your clinical review. At nume, a GPhC-registered prescriber reads your consultation before every repeat order, a real clinician, not a system rubber-stamping a form. That review is the right moment to flag that you've been on your current dose for four-plus weeks, that side effects have settled, and that your progress has levelled off.
What the prescriber will want to know: current weight and recent trend, any ongoing symptoms, how your appetite feels on this dose, and whether anything else has changed medically. If you're transferring from another provider and already at a higher dose, we ask for evidence of your current dose before continuing at that level, that's a safety standard, not bureaucracy.
There's more detail on how the semaglutide increase process works clinically in the guide to semaglutide dose timing, and the Wegovy increase page covers the practical steps involved. If you have a specific question before your next review, our team is available seven days a week through our aftercare line.
Ready to speak to someone? Speak to our prescribers through a free consultation, no waiting room, clinical review the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.